We are proud to announce that three members of our team have been recognized by Managing IP. Dr. Jacqueline Lui and Ms. Pauli Wong have been recognized as a Patent Star and Mr. Eddie Ho as a Rising Star by ManagingIP. These prestigious awards acknowledge their exceptional expertise and invaluable contributions to the field of intellectual property.

Dr. Lui is widely recognized as a leading expert in patent law, specializing in cross-jurisdiction patent prosecution and strategy. With over 20 years of experience in IP, she has provided invaluable guidance to startups, Fortune 500 companies, and HK/Nasdaq-listed companies. Her expertise encompasses various critical areas, including IP strategy, portfolio management, technology transfer, due diligence, and enforcement. Dr. Lui's exceptional track record and unwavering commitment to excellence have solidified her reputation as a trusted advisor in the field.

Ms. Pauli Wong oversees the patent drafting team at Eagle IP and assists local and international clients with patent prosecution across a wide range of technology fields. She helps clients navigate IP rights, portfolio management, and global filing strategy for innovations in areas like biotechnology, medical devices, and robotics. Pauli is passionate about empowering Hong Kong innovators, leveraging her ability to quickly understand new technologies, meticulous prosecution skills, strategic business acumen, and commitment to client service.

Mr. Eddie Ho is a qualified Chinese Patent Attorney and has quickly amassed extensive experience drafting and prosecuting patent applications in a broad range of areas, including biology, biotechnology, medical devices, diagnostics, material science, engineering, and software. He helps inventors and companies manage and navigate complex patent portfolios and is exceptionally strong at inter-disciplinary technologies.

Let us come together to celebrate this well-deserved accolade for Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho and to recognize their exceptional dedication to the dynamic world of intellectual property.

我们的过去活动

Recommended Insights

China Releases Details on Patent Term Extension, Deferred Examination and More in the Latest Draft Implementation Rules of the New Chinese Patent Law

2020年12月11日
The China National Intellectual Property Administration (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but […]

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

2018年11月12日
Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]

China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)

2021年4月30日
This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

AI, Big Data, and Blockchain - CNIPA seeks public comment on draft patent examination guidelines

2019年11月21日
Exciting new changes continue to happen with the Chinese Patent Office (CNIPA). On November 12, 2019, the CNIPA published a new set of amendments to Part II Chapter 9 of the Patent Examination Guidelines (“Draft”) and requested public comment by December 11, 2019. In summary, the new guidelines clarify how emerging technologies involving artificial intelligence, […]
Top crossarrow-right